ACUTE LYMPHOCYTIC LEUKEMIA
Clinical trials for ACUTE LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at returning blood cancers
Disease control OngoingThis early-phase trial tests the safety of giving patients modified immune cells from a donor to fight B-cell leukemia or lymphoma that has come back after a stem cell or organ transplant. The cells are designed to target a protein called CD19 on cancer cells. Only 19 patients ar…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New safety check for Kids' leukemia drug BESPONSA
Disease control OngoingThis study is checking the safety of the drug BESPONSA in children under 18 with a type of blood cancer called acute lymphocytic leukemia (ALL). The 10 participants have already been treated and are being watched for side effects, especially liver problems. The goal is to better …
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug aims to wipe out lingering leukemia cells after chemo
Disease control OngoingThis phase 2 trial tests the drug inotuzumab ozogamicin in 31 adults with B-cell acute lymphoblastic leukemia (ALL) who achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells detectable (called minimal residual disease, or MRD). The goal is to…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Blood cancer transplant trial using banked donor marrow pulled before start
Disease control TerminatedThis Phase 1 trial aimed to test whether bone marrow from deceased, mismatched unrelated donors could be safely used for transplants in patients with blood cancers like leukemia. The approach used stored (cryopreserved) marrow along with drugs to prevent rejection. However, the s…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New stem cell transplant approach shows promise for blood cancer patients without full matches
Disease control OngoingThis Phase 3 trial tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor in 21 people with various blood cancers. The goal was to see if this approach could help patients who don't have a fully matched donor. Participants received chemoth…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE3 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Engineered immune cells take aim at blood cancers
Disease control OngoingThis early-phase study tests a new treatment for people with certain B-cell blood cancers (lymphoma, ALL, or CLL) that have returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer ce…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can a pill make CAR T-Cells last longer?
Disease control OngoingThis early-phase trial tests whether the drug duvelisib can help CAR T-cells persist longer in people with non-Hodgkin lymphoma or acute lymphocytic leukemia. About 42 adults who have already received a standard CAR T-cell therapy will take duvelisib pills daily. The main goal is…
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Cord blood stem cells boost recovery in High-Risk cancer patients
Disease control OngoingThis study tests a new stem cell treatment (MGTA-456) made from umbilical cord blood for people with high-risk blood cancers like leukemia and lymphoma. About 22 patients will receive high-dose chemotherapy followed by the stem cell infusion. The goal is to see if this treatment …
Matched conditions: ACUTE LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC